Population pharmacokinetic characterization of BAY 81-8973 published in Haemophilia

Model Answers contributes towards new research in Haemophilia with development of a population pharmacokinetic model for Kovaltry, highlighting the importance of including data below the limit of quantification for Factor VIII.

Abstract

Introduction; the pharmacokinetics (PK), safety and efficacy of BAY 81-8973, a full-length, unmodified, recombinant human factor VIII (FVIII), were evaluated in the LEOPOLD trials.Aim; the aim of this study was to develop a population PK model based on pooled data from the LEOPOLD trials and to investigate the importance of including samples with FVIII levels below the limit of quantitation (BLQ) to estimate half-life.Methods; the analysis included 1535 PK observations (measured by the chromogenic assay) from 183 male patients with haemophilia A aged 1‒61 years from the 3 LEOPOLD trials. The limit of quantitation was 1.5 IU dL−1 for the majority of samples. Population PK models that included or excluded BLQ samples were used for FVIII half-life estimations, and simulations were performed using both estimates to explore the influence on the time below a determined FVIII threshold.Results; in the data set used, approximately 16.5% of samples were BLQ, which is not uncommon for FVIII PK data sets. The structural model to describe the PK of BAY 81-8973 was a two-compartment model similar to that seen for other FVIII products. If BLQ samples were excluded from the model, FVIII half-life estimations were longer compared with a model that included BLQ samples.Conclusions; it is essential to assess the importance of BLQ samples when performing population PK estimates of half-life for any FVIII product. Exclusion of BLQ data from half-life estimations based on population PK models may result in an overestimation of half-life and underestimation of time under a predetermined FVIII threshold, resulting in potential underdosing of patients.